For ulcerative colitis, is subcutaneous guselkumab administered every 4 weeks or every 8 weeks more appropriate?

Guselkumab Maintenance Dosing for Ulcerative Colitis

For ulcerative colitis maintenance therapy, guselkumab 200 mg subcutaneously every 4 weeks is superior to 100 mg every 8 weeks, achieving higher clinical remission rates (50% vs 45%) with significantly greater drug exposure and comparable safety. 1

Evidence-Based Recommendation

The 2024 AGA guidelines provide the clearest head-to-head comparison from the QUASAR maintenance trial 1:

• 200 mg SC every 4 weeks: 50.0% clinical remission at week 44 (95/190 patients)
• 100 mg SC every 8 weeks: 45.2% clinical remission at week 44 (85/188 patients)
• Placebo: 18.9% clinical remission (36/190 patients)

Both dosing regimens demonstrated statistically significant superiority over placebo with moderate certainty evidence (GRADE ⨁⨁⨁), but the every-4-week regimen showed numerically higher absolute benefit (246 more per 1000 vs 209 more per 1000 compared to placebo).

Pharmacokinetic Rationale

The FDA label data strongly supports the every-4-week regimen based on drug exposure 2:

• 100 mg every 8 weeks: Mean steady-state trough concentration ~1.4 mcg/mL
• 200 mg every 4 weeks: Mean steady-state trough concentration ~10.7 mcg/mL

This represents approximately 7.6-fold higher drug exposure with the every-4-week regimen, providing more consistent IL-23 blockade throughout the dosing interval.

Clinical Context and Nuances

When to Choose Each Regimen:

Prefer 200 mg every 4 weeks for:

• Patients with more severe baseline disease activity
• Those with prior biologic failure (higher disease burden)
• Patients requiring maximal disease control to avoid colectomy
• Those who had suboptimal response during induction

Consider 100 mg every 8 weeks for:

• Patients achieving deep remission during induction
• Those with milder disease at maintenance baseline
• Situations where cost or injection burden is prohibitive
• Patients concerned about injection frequency

Important Caveats:

The British Society of Gastroenterology 2025 guidelines note that ustekinumab (another IL-23 inhibitor) showed only "trivial benefit" with every-12-week dosing but "small benefit" with every-8-week dosing 3. This pattern suggests that more frequent dosing of IL-23 inhibitors in UC provides clinically meaningful advantages, supporting the every-4-week guselkumab regimen.

Safety Profile

Both maintenance regimens demonstrated comparable safety profiles in the QUASAR program 4:

• No dose-dependent increase in adverse events
• No active tuberculosis, anaphylaxis, or clinically significant hepatic disorders
• Most common adverse events: UC flare, COVID-19, arthralgia

The higher drug exposure with every-4-week dosing did not translate to increased safety concerns, making it the preferred option when maximal efficacy is needed.

Practical Algorithm

1. After successful induction: Assess depth of response
2. If deep remission achieved (clinical + endoscopic + biochemical): Consider starting with 100 mg every 8 weeks
3. If partial response or high-risk features: Start with 200 mg every 4 weeks
4. If loss of response on 100 mg every 8 weeks: Intensify to 200 mg every 4 weeks (supported by ustekinumab dose intensification data showing benefit of every-4-week dosing) 5

The default recommendation should be 200 mg every 4 weeks given the superior remission rates and substantially higher drug exposure without additional safety concerns, particularly in the moderate-to-severe UC population where preventing disease progression and colectomy are paramount outcomes.